Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer

NEXT STORY
Cell Culture Market Size to Reach USD 45.12 Billion in 2027 | Rising Demand for Monoclonal Antibodies, Growing Preference for Customized Therapies are Some Major Factors Driving Industry Growth, says Emergen Research
PREV STORY
electroCore Announces Top Line Results from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Lactation Rooms Added to the ABOG Educational Foundation Test Center

Certifying Exam Candidates and Examiners Provide Positive Feedback About the AccommodationsDallas, Texas, Feb. 05, ...

author_avatar
NASDAQ Market News

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

author_avatar
NASDAQ Market News